Showing 1691-1700 of 2314 results for "".
- Eversight to Offer Preloaded DMEK in DORC Tubehttps://modernod.com/news/eversight-first-to-offer-preloaded-dmek-in-dorc-tube/2476911/Eversight announced it is the first eye bank to prepare preloaded Descemet membrane endothelial keratoplasty (DMEK) tissue in the Melles DORC tube, offering corneal surgeons more preloaded tissue options that further streamline surgeries and reduce cost, according to a company news release. <
- ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosahttps://modernod.com/news/proqr-receives-fast-track-designation-from-fda-for-qr-1123-for-autosomal-dominant-retinitis-pigmentosa/2479540/ProQR Therapeutics announced that it received fast track designation from the FDA for QR-1123, a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H mutation
- Study: Yellow Lens Glasses Don’t Improve Drivers’ Night Visionhttps://modernod.com/news/study-yellow-lens-glasses-dont-improve-drivers-night-vision/2476789/Touted to improve nighttime eyesight, yellow lens glasses don’t help drivers see better and may, in fact, worsen vision, a new study suggests, Reuters Health reported. Researchers found that yellow-lens wearing volunteers ope
- BioTime Initiates Dosing in Phase 1/2a Clinical Study of OpRegen for Treatment of Dry AMDhttps://modernod.com/news/biotime-initiates-dosing-in-phase-1-2a-clinical-study-of-opregen-for-treatment-of-dry-amd/2476722/BioTime announced that it has dosed its first patient with the Orbit Subretinal Delivery System (Orbit SDS) as well as with a new thaw-and-inject formulation of OpRegen, the company’s retinal pigment epithelium (RPE) transplant therapy, in its ongoing phase 1/2a clinical study for the treatment o
- DORC Announces FDA Acceptance of Orphan NDA for Brilliant Blue G Ophthalmic Solutionhttps://modernod.com/news/dorc-announces-fda-acceptance-of-orphan-nda-for-brilliant-blue-g-ophthalmic-solution/2476701/DORC has announced that it has received notification from the FDA that their new drug application (NDA) for Brilliant Blue G ophthalmic solution has been accepted for review. The proposed indication for Brillia
- Dompé Announces First Patient Enrolled in Phase 2b Clinical Trial Investigating Dry Eye Disease Drug Candidatehttps://modernod.com/news/dompe-announces-first-patient-enrolled-in-phase-2b-clinical-trial-investigating-dry-eye-disease-drug-candidate/2476687/Dompé Farmaceutici S.p.A and Dompé U.S. announced that the first patient has been enrolled in NGF0118, a multicenter, randomized, double-masked, vehicle-controlled, parallel group study to evaluate the safety and efficacy of rhNGF eye solution vs. vehicle in patients with moderate to severe dry e
- First Patient Dosed in Phase 2 Trial Evaluating Ocular Delivery of ST266 For the Treatment of Persistent Corneal Epithelial Defectshttps://modernod.com/news/noveome-biotherapeutics-announces-the-first-patient-dosed-in-phase-2-open-label-clinical-trial-evaluating-topical-ocular-delivery-of-st266-for-the-treatment-of-persistent-corneal-epithelial-defects/2476652/Noveome Biotherapeutics announced the dosing of the first patient in its phase 2 open label, multicenter clinical trial evaluating topical ocular delivery of ST266 for the treatment of persistent corneal epithelial defects (PEDs), for which there are limited treatment options. “The dosing
- Nicox Presents First Data on New Class of Nitric Oxide (NO)-Donating Compounds for Glaucoma at ARVOhttps://modernod.com/news/nicox-presents-first-data-on-new-class-of-nitric-oxide-no-donating-compounds-for-glaucoma-at-arvo/2476545/Nicox SA announced that it has presented the first data from a new drug class designed to lower IOP (NO-donating PDE5 inhibitors) at a poster presentation during the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The first
- Innovent Announces First Patient Dosed in a Phase 1 Clinical Trial of IBI302 for the Treatment of Wet AMDhttps://modernod.com/news/innovent-announces-first-patient-dosed-in-a-phase-1-clinical-trial-of-ibi302-for-the-treatment-of-wet-amd/2476478/Innovent Biologics announced that the first patient has been successfully dosed in a phase 1 clinical trial of IBI302, a novel recombinant fully human bispecific fusion protein targeting both vascular endothelium growth factor (VEGF) and complement proteins, for the treatment of wet age-related m
- Eurazeo Capital to Acquire DORC From Montaguhttps://modernod.com/news/eurazeo-capital-to-acquire-dorc-from-montagu/2476442/Eurazeo Capital will acquire ophthalmic instrument maker DORC (Dutch Ophthalmic Research Center) from Montagu Private Equity for about EUR300 million. Established in 1983 and headquartered in the Netherlands, DORC is a specialist in vitreoretinal surgery,